#New York #Faruqi & Faruqi #Rocket Pharmaceuticals #RCKT

Faruqi & Faruqi Calls Attention to Rocket Pharmaceuticals Class Action Lawsuit

Faruqi & Faruqi, LLP, a prominent national securities law firm, has issued an important reminder to investors regarding a pending class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This alert is particularly crucial for shareholders who experienced financial losses as a result of investments made between February 27, 2025, and May 26, 2025. With the lead plaintiff deadline set for August 11, 2025, those impacted are encouraged to evaluate their legal options in this matter.

Overview of the Case

The law firm's recent investigation reveals that Rocket Pharmaceuticals made several misleading statements regarding the safety and clinical trial protocols for its product, RP-A501. Such declarations were made while crucial adverse realities were withheld from investors, including the knowledge that serious adverse events (SAEs) were occurring during clinical trials. Notably, this misrepresentation culminated in tragic outcomes, including patient fatalities during trials of the treatment.

On May 27, 2025, the company announced that the FDA had placed a hold on the Phase 2 pivotal study for RP-A501 after severe complications arose, one resulting in a patient's death. This shocking news came after significant amendments to the trial’s protocol had been made without notifying shareholders. In fact, the firm's communications suggested that management had decided on the alterations